Literature DB >> 31668160

Physicians' attitudes towards accelerated access to medicines.

Jessica Pace1, Ian Kerridge1, Sallie Pearson2, Wendy Lipworth1.   

Abstract

In recent years, a variety of 'accelerated access' schemes have been introduced by pharmaceutical regulators and funders globally. These schemes aim to overcome perceived regulatory and reimbursement barriers to accessing medicines - particularly for patients with limited time or therapeutic options. However, patient access to approved medicines is mediated by a number of third parties including regulators and payers, and physicians who act both as gatekeepers and guides to prescribed medications. It is therefore essential to know how physicians think about accelerated access as they are responsible for advising patients on and prescribing medicines made available via these pathways. We conducted semi-structured interviews with 18 Australian physicians focusing on their attitudes towards accelerated access. We identified three 'archetypes' of physicians: 'confident accelerators', 'cautious accelerators', and 'decelerators'. Although all acknowledged the potential risks and benefits of accelerated access, they disagreed on their magnitude and extent and how they should be balanced in both policy formation and clinical practice. Overall, our results illustrate the diversity of clinical opinions in this area and the importance of monitoring both the prescribing and clinical outcomes that result from accelerated access programmes to ensure that these are both clinically and morally acceptable.

Entities:  

Keywords:  Accelerated access; conditional registration; coverage with evidence development; pharmaceutical funding; pharmaceutical regulation

Mesh:

Substances:

Year:  2019        PMID: 31668160     DOI: 10.1017/S1744133119000288

Source DB:  PubMed          Journal:  Health Econ Policy Law        ISSN: 1744-1331


  1 in total

1.  Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.

Authors:  Jeremiah Stout; Cambray Smith; Jan Buckner; Alex A Adjei; Mark Wentworth; Jon C Tilburt; Zubin Master
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.